Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9430893 | 0.90 | AR (0.63) | ARCYP2C19 | |
| SCHEMBL7518469 | 0.89 | ABCC9 (0.64) | ARCYP2C19 | |
| SCHEMBL6242747 | 0.89 | AR (0.62) | ARCYP2C19 | |
| SCHEMBL15362806 | 0.89 | AR (0.61) | ARCYP2C19 | |
| SCHEMBL30173705 | 0.89 | AR (0.61) | ARCYP2C19 | |
| SCHEMBL31531532 | 0.88 | AR (0.61) | ARCYP2C19 | |
| SCHEMBL16845620 | 0.88 | AR (0.64) | ARCYP2C19 | |
| SCHEMBL31026332 | 0.88 | AR (0.64) | ARCYP2C19 | |
| SCHEMBL2980069 | 0.87 | AR (0.59) | ARCYP2C19 | |
| SCHEMBL20113379 | 0.87 | AR (0.69) | ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0002309-B1 | ACYLANILIDES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-01 | — | — | EP | claimed |
| US-4239776-A | Anti-androgenic amides | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-12-16 | — | — | US | claimed |
| EP-0002309-A2 | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-06-13 | — | — | EP | claimed |
| US-20230002326-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| WO-2022174121-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | VERU, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3976577-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2020243373-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200222365-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200039924-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2008013791-A2 | PAN-ANTAGONISTS FOR THE ANDROGEN RECEPTOR AND ANDROGEN RECEPTOR MUTANTS ASSOCIATED WITH ANTI-ANDROGEN WITHDRAWAL | UNIVERSITY OF DELAWARE (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007057909-A1 | ANDROGEN-RECEPTOR (AR) LIGANDS FOR USE IN THE TREATMENT AND DIAGNOSIS OF AR-RELATED PATHOLOGIES | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2007-05-24 | — | — | WO | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0002309-B1 | ACYLANILIDES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
| US-4282218-A | ANTIANDROGENS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-08-04 | — | — | US | disclosed |
| US-4239776-A | Anti-androgenic amides | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-12-16 | — | — | US | disclosed |
| EP-0002309-A2 | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885CYP2C19 1317/4885 |
| US-20230002326-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | AR 1/4885CYP2C19 820/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885 |
| US-20200222365-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885 |
| US-20200039924-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | AR 1/4885CYP2C19 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.